WST
Income statement / Annual
Last year (2024), West Pharmaceutical Services, Inc.'s total revenue was $2.89 B,
a decrease of 1.98% from the previous year.
In 2024, West Pharmaceutical Services, Inc.'s net income was $492.70 M.
See West Pharmaceutical Services, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$2.89 B |
$2.95 B |
$2.89 B |
$2.83 B |
$2.15 B |
$1.84 B |
$1.72 B |
$1.60 B |
$1.51 B |
$1.40 B |
| Cost of Revenue |
$1.89 B
|
$1.82 B
|
$1.75 B
|
$1.66 B
|
$1.38 B
|
$1.23 B
|
$1.17 B
|
$1.09 B
|
$1.01 B
|
$943.90 M
|
| Gross Profit |
$1.00 B
|
$1.13 B
|
$1.14 B
|
$1.17 B
|
$767.90 M
|
$608.80 M
|
$546.30 M
|
$514.80 M
|
$501.00 M
|
$454.10 M
|
| Gross Profit Ratio |
0.35
|
0.38
|
0.39
|
0.41
|
0.36
|
0.33
|
0.32
|
0.32
|
0.33
|
0.32
|
| Research and Development Expenses |
$69.10 M
|
$68.40 M
|
$58.50 M
|
$52.80 M
|
$46.90 M
|
$38.90 M
|
$40.30 M
|
$39.10 M
|
$36.80 M
|
$34.10 M
|
| General & Administrative Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$338.50 M
|
$353.40 M
|
$316.90 M
|
$361.90 M
|
$302.00 M
|
$272.70 M
|
$262.90 M
|
$246.00 M
|
$239.80 M
|
$233.00 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$11.70 M
|
$0.00
|
$8.90 M
|
$61.30 M
|
| Operating Expenses |
$407.60 M
|
$421.80 M
|
$375.40 M
|
$414.70 M
|
$348.90 M
|
$311.60 M
|
$291.50 M
|
$285.10 M
|
$285.50 M
|
$328.40 M
|
| Cost And Expenses |
$2.30 B
|
$2.24 B
|
$2.12 B
|
$2.07 B
|
$1.73 B
|
$1.55 B
|
$1.46 B
|
$1.37 B
|
$1.29 B
|
$1.27 B
|
| Interest Income |
$19.60 M
|
$28.00 M
|
$5.10 M
|
$1.00 M
|
$1.40 M
|
$3.80 M
|
$2.10 M
|
$1.30 M
|
$1.10 M
|
$1.60 M
|
| Interest Expense |
$2.90 M
|
$8.80 M
|
$7.60 M
|
$8.50 M
|
$8.50 M
|
$8.00 M
|
$8.10 M
|
$7.10 M
|
$6.40 M
|
$11.70 M
|
| Depreciation & Amortization |
$155.40 M
|
$137.30 M
|
$120.60 M
|
$122.30 M
|
$109.10 M
|
$103.40 M
|
$104.40 M
|
$96.70 M
|
$90.70 M
|
$89.90 M
|
| EBITDA |
$743.80 M |
$844.10 M |
$808.10 M |
$879.70 M |
$518.90 M |
$403.20 M |
$353.20 M |
$326.20 M |
$286.90 M |
$217.70 M |
| EBITDA Ratio |
0.26
|
0.29
|
0.28
|
0.31
|
0.24
|
0.22
|
0.21
|
0.2
|
0.19
|
0.16
|
| Operating Income Ratio |
0.21
|
0.24
|
0.26
|
0.27
|
0.2
|
0.16
|
0.15
|
0.14
|
0.14
|
0.09
|
| Total Other Income/Expenses Net |
$5.60 M
|
$4.80 M
|
-$62.90 M
|
$10.30 M
|
-$300.00 K
|
$3.50 M
|
-$6.50 M
|
$1.90 M
|
-$17.50 M
|
-$3.80 M
|
| Income Before Tax |
$600.20 M
|
$715.70 M
|
$700.60 M
|
$769.00 M
|
$418.70 M
|
$300.70 M
|
$248.30 M
|
$231.60 M
|
$198.00 M
|
$121.90 M
|
| Income Before Tax Ratio |
0.21
|
0.24
|
0.24
|
0.27
|
0.2
|
0.16
|
0.14
|
0.14
|
0.13
|
0.09
|
| Income Tax Expense |
$107.50 M
|
$122.30 M
|
$114.70 M
|
$107.20 M
|
$72.50 M
|
$59.00 M
|
$41.40 M
|
$80.90 M
|
$54.40 M
|
$26.30 M
|
| Net Income |
$492.70 M
|
$593.40 M
|
$585.90 M
|
$661.80 M
|
$346.20 M
|
$241.70 M
|
$206.90 M
|
$150.70 M
|
$143.60 M
|
$95.60 M
|
| Net Income Ratio |
0.17
|
0.2
|
0.2
|
0.23
|
0.16
|
0.13
|
0.12
|
0.09
|
0.1
|
0.07
|
| EPS |
6.75 |
7.99 |
7.88 |
8.9 |
4.68 |
3.27 |
2.8 |
2.04 |
1.96 |
1.33 |
| EPS Diluted |
6.69 |
7.88 |
7.73 |
8.67 |
4.57 |
3.21 |
2.74 |
1.99 |
1.91 |
1.3 |
| Weighted Average Shares Out |
$73.00 M
|
$74.30 M
|
$74.40 M
|
$74.40 M
|
$73.90 M
|
$74.00 M
|
$73.90 M
|
$73.90 M
|
$73.30 M
|
$72.00 M
|
| Weighted Average Shares Out Diluted |
$73.70 M
|
$75.30 M
|
$75.80 M
|
$76.30 M
|
$75.80 M
|
$75.40 M
|
$75.40 M
|
$75.80 M
|
$75.00 M
|
$73.80 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
